Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELU 001

Next Previous
Drug Profile

ELU 001

Alternative Names: ELU-001

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elucida Oncology
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Folic acids; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Acute myeloid leukaemia
  • No development reported Ovarian cancer

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for preclinical development in Ovarian-cancer(Treatment-resistant) in USA (Parenteral)
  • 07 Jun 2024 Elucida Oncology terminates phase I/II trial in Solid tumors in USA due to lack of funding (Company Bankruptcy) and not a safety issue with drug (NCT05001282)
  • 08 Dec 2023 Elucida Oncology withdraws a phase I trial for Acute myeloid leukemia (In children, In infants, Second-line therapy or greater) prior to enrollment (IV,Infusion) (NCT05622591)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top